ERBB2 and breast carcinoma: However, the finding that human ErbB2 polymorphisms can affect breast cancer prevalence suggests that the study of transmembrane activating ErbB2 mutations in animals (in the absence of amplification/over-expression) may prove beneficial in the context of human disease.